[1] National Health Commission. Diagnosis and treatment protocol for COVID-19 (Trial Version 5). http://www.nhc.gov.cn/xcs/zhengcwj/202002/3b09b894ac9b4204a79db5b8912d4440.shtml. [2020-2-5]. (In Chinese). http://www.nhc.gov.cn/xcs/zhengcwj/202002/3b09b894ac9b4204a79db5b8912d4440.shtml
[2] Moncunill G, Mayor A, Santano R, Jiménez A, Vidal M, Tortajada M, et al. SARS-CoV-2 seroprevalence and antibody kinetics among health care workers in a Spanish hospital after 3 months of follow-up. J Infect Dis 2021;223(1):62 − 71. http://dx.doi.org/10.1093/infdis/jiaa696CrossRef
[3] He ZY, Ren LL, Yang JT, Guo L, Feng LZ, Ma C, et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. Lancet 2021;397(10279):1075 − 84. http://dx.doi.org/10.1016/S0140-6736(21)00238-5CrossRef
[4] Zhou W, Xu XM, Chang ZG, Wang H, Zhong XF, Tong XL, et al. The dynamic changes of serum IgM and IgG against SARS-CoV-2 in patients with COVID-19. J Med Virol 2021;93(2):924 − 33. http://dx.doi.org/10.1002/jmv.26353CrossRef